Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer care through innovative diagnostic and therapeutic solutions. The company's CELsignia diagnostic platform analyzes living tumor cells from patients to identify the specific abnormal cellular processes driving their cancer, enabling personalized treatment options. Celcuity is developing the CELsignia HSF test to diagnose new sub-types of HER2-negative breast cancer, as well as the CELsignia MP test to identify multiple cancer sub-types across various types, including breast, lung, colon, ovarian, kidney, and bladder cancers. In addition to its diagnostic efforts, Celcuity is advancing a lead therapeutic candidate, gedatolisib, a potent pan-PI3K and mTOR inhibitor, which is currently being evaluated in a Phase 3 clinical trial for patients with HR+/HER2- advanced breast cancer. Founded in 2011, Celcuity aims to transform the treatment landscape for patients with cancer by providing targeted therapies tailored to their unique disease profiles.
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated the best-in-class platform and initiated multiple programs across different disease areas.
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergies and inflammation. The company is focused on creating first-in-class oral small-molecule inhibitors targeting the KIT receptor, which plays a crucial role in the survival and function of mast cells—key immune cells involved in allergic responses. Its lead product candidate, THB001, is designed to provide selective inhibition of KIT, while another candidate, THB335, aims to address multiple mast cell-driven inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to advance the management of inflammatory diseases, enhancing patient outcomes and quality of life.
NanoMosaic specializes in innovative solutions for early illness detection, prognostic monitoring, and biomarker identification. The company has developed a unique platform that utilizes nanoneedles for protein detection and quantification. This technology facilitates the analysis of multiple biomarkers on a single chip, making it possible for the medical and healthcare sectors to enhance the speed and accuracy of biomarker discovery and validation. By enabling more efficient proteomic analysis, NanoMosaic aims to improve early disease detection and monitoring, ultimately contributing to better health outcomes.
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Sydnexis specializes in developing a proprietary treatment for pediatric progressive myopia, addressing a significant global medical need. The company manufactures a topical eyedrop formulation aimed at treating this condition in children, allowing healthcare professionals to effectively manage and reduce the progression of myopia. Through its innovative approach, Sydnexis seeks to enhance eye care for pediatric patients and mitigate the prevalence of eye disorders in this demographic.
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, specializing in the development of therapeutic drugs for hyperexcitability disorders. Founded in 2018, the company focuses on creating innovative analgesics aimed at addressing unmet medical needs in conditions such as chronic pain, psychiatric disorders, and epilepsy. Eliem's key drug candidate, ETX-155, targets major depressive disorder and focal onset seizures, reflecting the company's commitment to advancing neuroscience and translational medicine. Through its research and development efforts, Eliem Therapeutics aims to improve the quality of life for patients suffering from these challenging conditions.
Ceribell, Inc. specializes in the design and manufacture of medical devices aimed at acquiring and interpreting electroencephalography (EEG) data for patients with neurological conditions. The company offers the Ceribell EEG System, which includes a versatile EEG headband accommodating various hair types and head sizes, and a compact, battery-operated EEG recorder that delivers clinical-quality data with an on-device display. Ceribell focuses on improving the accessibility and efficiency of EEG technology by developing an FDA-cleared instant EEG system that can be set up by any healthcare provider in just six minutes, eliminating the need for specialized technologists. This system features a unique Brain Stethoscope function that converts brainwaves into sound, allowing for the detection of seizures through auditory means. By facilitating earlier diagnoses and targeted treatments for seizures, including non-convulsive seizures, Ceribell aims to enhance patient outcomes while reducing risks such as mortality and complications. Founded in 2014 and based in Mountain View, California, Ceribell is committed to transforming the diagnosis and management of serious neurological conditions in acute care settings.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, specializing in the development of therapeutic drugs for hyperexcitability disorders. Founded in 2018, the company focuses on creating innovative analgesics aimed at addressing unmet medical needs in conditions such as chronic pain, psychiatric disorders, and epilepsy. Eliem's key drug candidate, ETX-155, targets major depressive disorder and focal onset seizures, reflecting the company's commitment to advancing neuroscience and translational medicine. Through its research and development efforts, Eliem Therapeutics aims to improve the quality of life for patients suffering from these challenging conditions.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Abcuro, Inc. is focused on developing immunotherapies aimed at treating autoimmunity and cancer. Incorporated in 2015 and based in Newton, Massachusetts, the company specializes in creating therapeutic antibodies that target novel aspects of the immune system. By employing advanced bioinformatics and analyzing transcription data from human diseases, Abcuro identifies new therapeutic targets and validates them through ex-vivo studies in diseased tissues. This innovative approach aims to enhance treatment strategies and improve patient outcomes in the fields of autoimmunity and oncology.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Adagio Medical specializes in the design and manufacture of medical devices aimed at treating cardiac arrhythmias. Founded in 2011 and based in Laguna Hills, California, the company is dedicated to the research and development of innovative cryoablation catheters. These devices are engineered to create safe, continuous, transmural lesions that effectively address various cardiac conditions, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. Adagio Medical's product offerings include the continuous lesion ablation system (iCLAS), specialized catheters, esophageal balloons, and consoles, all developed to enhance the capabilities of electrophysiologists in the treatment of cardiovascular diseases.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, specializing in the development of therapeutic drugs for hyperexcitability disorders. Founded in 2018, the company focuses on creating innovative analgesics aimed at addressing unmet medical needs in conditions such as chronic pain, psychiatric disorders, and epilepsy. Eliem's key drug candidate, ETX-155, targets major depressive disorder and focal onset seizures, reflecting the company's commitment to advancing neuroscience and translational medicine. Through its research and development efforts, Eliem Therapeutics aims to improve the quality of life for patients suffering from these challenging conditions.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
WhiteSwell Limited provides cardiology services. The company offers treatment for acute decompensated hearth failure (ADHF). Its treatment is a catheter-based approach to remove excess tissue fluid in patients with ADHF, without comprising renal function. The company was founded in 2014 and is based in Galway, Ireland with additional offices in Shefayim, Israel and Palo Alto, California
Farcast is a clinical diagnostic company dedicated to providing personalized cancer treatment solutions. Its core technology utilizes a human tumor microenvironment to enable oncologists and drug developers to assess individual tumors and determine their treatment response profiles. This innovative approach aims to surpass traditional biomarker-guided strategies, thereby enhancing access to personalized medicine and improving the clinical management of cancer. Headquartered in Boston, Massachusetts, Farcast also operates a laboratory in Bangalore, India, reflecting its commitment to advancing cancer care through cutting-edge technology.
Imbria Pharmaceuticals, Inc. is a Boston-based pharmaceutical company founded in 2018, dedicated to developing innovative treatments that enhance or restore cellular energy production. Focused on addressing life-altering cardiometabolic disorders, Imbria's therapies aim to improve outcomes for patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. The company operates at the clinical stage, leveraging a deep scientific understanding of cellular metabolism and mitochondrial function to create novel medicines. Founded and led by a team of doctors, Imbria is committed to translating scientific insights into effective therapies that address significant unmet medical needs, prioritizing the well-being of patients and their communities.
CiVi Biopharma is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and metabolic diseases, particularly those with significant unmet medical needs. The company is advancing multiple assets in its pipeline, including Intravenous Iloprost, which is currently undergoing Phase 3 trials for the treatment of Systemic Sclerosis. By concentrating on both cardiovascular and rare diseases, CiVi Biopharma aims to provide valuable therapeutic options that enhance patient care and improve health outcomes.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Medeor Therapeutics, Inc. specializes in the research, development, and commercialization of personalized cellular immunotherapies aimed at enhancing outcomes for organ transplant recipients. The company focuses on creating innovative cellular immunotherapy products, particularly for kidney transplant patients, under the MDR-10X brand. By employing advanced approaches to organ transplant immune tolerance and immuno-oncology, Medeor Therapeutics seeks to improve kidney function and reduce the risk of graft rejection more effectively than traditional immunosuppressive medications. Founded in 2012, the company is headquartered in San Mateo, California.
Sydnexis specializes in developing a proprietary treatment for pediatric progressive myopia, addressing a significant global medical need. The company manufactures a topical eyedrop formulation aimed at treating this condition in children, allowing healthcare professionals to effectively manage and reduce the progression of myopia. Through its innovative approach, Sydnexis seeks to enhance eye care for pediatric patients and mitigate the prevalence of eye disorders in this demographic.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Janssen, a subsidiary of Johnson & Johnson, is a pharmaceutical company focused on transforming healthcare through innovative medicines and solutions. Founded in 1953 by Dr. Paul Janssen, the company conducts extensive research and development across various therapeutic areas, including oncology, mental health, neurological disorders, gastrointestinal issues, and immunology. Janssen aims to address serious health concerns by delivering effective and affordable treatments, ensuring that patients have access to the best available care. The company is committed to improving healthcare delivery and patient outcomes through the integration of new technologies and consumer empowerment. By addressing unmet medical needs, Janssen continues to advance the science of medicine while striving to create a healthier world for all.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Farcast is a clinical diagnostic company dedicated to providing personalized cancer treatment solutions. Its core technology utilizes a human tumor microenvironment to enable oncologists and drug developers to assess individual tumors and determine their treatment response profiles. This innovative approach aims to surpass traditional biomarker-guided strategies, thereby enhancing access to personalized medicine and improving the clinical management of cancer. Headquartered in Boston, Massachusetts, Farcast also operates a laboratory in Bangalore, India, reflecting its commitment to advancing cancer care through cutting-edge technology.
Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.
SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of a high- energy, focused, shock wave technology that is used in devices for the repair and regeneration of bones, muscles, tendons and skin, and for the separation of solids and fluid in non-medical systems. Within healthcare, SANUWAVE’s proprietary, patented Pulsed Acoustic Cellular Expression (PACE) technology emits high-energy, acoustic shock waves that restore the body’s normal healing processes. This activates biologic signaling which leads to tissue repair and regeneration and blood vessel growth – revascularization and microcirculatory enhancement. SANUWAVE has three devices that employ the PACE technology. The lead device for the global wound care market, dermaPACE®, is approved for use outside the United States (CE Marked) for advanced wound care indications and is currently being studied in a U.S-based supplemental pivotal clinical trial for diabetic foot ulcers. The orthoPACE® device is CE Marked for orthopedic and musculoskeletal indications. OssaTron®, the Company’s legacy device, is approved by the FDA for multiple orthopedic conditions which have failed to respond to conservative treatment. In addition, SANUWAVE has patented the use of its shock wave technology in non-medical fields, including energy (improved/enhanced oil recovery), water (purification), food (bacterial reduction), and industrial effluent (particulate separation), and is working toward licensing/partnership relationships.
Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.
Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life. The product development portfolio of the Company includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications, and is being evaluated in two ongoing clinical trials, and has been authorized for use in a third clinical trial. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.
Provider of hospice services for patients in the Merrimack Valley and Southeastern Massachusetts. The company through an interdisciplinary team of physicians, nurses, home healthcare aides, social workers, counselors and volunteers provides palliative care for patients with terminal illnesses.